Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 7/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428774 | 0.91 | CREBBP (0.64) | CREBBPTRPV1HDAC1HDAC6MCHR1 | |
| SCHEMBL4429181 | 0.88 | CREBBP (0.61) | CREBBPTRPV1HDAC1HDAC6MCHR1 | |
| SCHEMBL4435517 | 0.85 | CREBBP (0.65) | CREBBPTRPV1HDAC1HDAC6MCHR1 | |
| SCHEMBL4433775 | 0.85 | CREBBP (0.62) | CREBBPTRPV1HDAC1HDAC6MCHR1 | |
| SCHEMBL13930018 | 0.84 | CREBBP (0.67) | CREBBPTRPV1HDAC1HDAC6MCHR1 | |
| SCHEMBL4432756 | 0.84 | CREBBP (0.63) | CREBBPTRPV1HDAC1HDAC6MCHR1 | |
| SCHEMBL13929832 | 0.83 | CREBBP (0.59) | CREBBPTRPV1HDAC1HDAC6MCHR1 | |
| SCHEMBL4435521 | 0.81 | CREBBP (0.60) | CREBBPTRPV1HDAC1HDAC6MCHR1 | |
| SCHEMBL4430220 | 0.81 | AVPR2 (0.61) | CREBBPTRPV1HDAC1HDAC6MCHR1 | |
| SCHEMBL4434512 | 0.81 | CREBBP (0.73) | CREBBPTRPV1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | CREBBP 1594/4885TRPV1 1/4885HDAC1 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.